R. Kim

Molecular Biology · Clinical pharmacology and therapy · 2001–2015

A researcher in the Science corpus: 8 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom R. Kim trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. A. Hopkins

Papers from R. Kim's perspective

Ordered by how strongly the researchers R. Kim trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. (Proceedings of the National Academy of Sciences of the United States of America)
  2. DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs
  3. The druggable genome (Nature reviews. Drug discovery)
  4. Exome sequencing as a tool for Mendelian disease gene discovery
  5. Identification of functionally variant MDR1 alleles among European Americans and African Americans (Clinical pharmacology and therapy)
  6. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. (Pharmacology and Therapeutics)
  7. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients (AIDS (London))
  8. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. (Pharmacogenetics (London))
  9. Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects (Clinical pharmacology and therapy)
  10. The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6… (Journal of Pharmacology and Experimental Therapeutics)

Their papers